Morgan Stanley Raises Alpharma Outlook

Analyst Marc Goodman likes the generics drug maker's prospects, and notes strong revenue and earnings growth

Morgan Stanley raised its estimates and the price target on Alpharma (ALO ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.